Endocrine Oncology, Pituitary Disorders
Temozolomide in the Treatment of Aggressive Pituitary Tumors— An Overview of Existing Knowledge and Future Perspectives
Ann McCormack
Pituitary tumors are common, with an estimated prevalence of 16.7 % in the general population based on imaging and autopsy studies.1 Clinically significant pituitary tumors are more prevalent than previously recognized, with one case per 1,000–1,300 people.2,3 The majority of pituitary tumors are indolent, slow-growing neoplasms.